Skip to main content

Miller Joseph M's Form 4 filing

Aurinia Pharmaceuticals Inc. (AUPH) · filed Mar 6, 2023

Accession no.
0001628280-23-006531
Filed
Mar 6, 2023
Trade date
Mar 2, 2023
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 2 non-derivative transactions. Open-market sales total $101.0K. It was filed 4 days after the trade.

This filing was later replaced by the amendment 0001600620-24-000014 (Feb 22, 2024). Trade tables on this site use the amended version.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Miller Joseph MCIK 0001746372Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 2, 2023Common StockAGrant or awardAcquired+229,421–F2–342,510Direct
Mar 2, 2023Common StockSSaleDisposed−11,296$8.94−$100,986.24331,214Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Each RSU represents a contingent right to receive one share of the Issuer's common stock.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)